
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is a highly attractive investment opportunity, with a strong technological differentiation and a potentially transformative TAM for its CGM systems in the T2NIT patient market. The recent CONNECT RCT results have only reinforced this potential, with significant A1c and TIR improvements across various treatment regimens, high CGM utilization rates, and potential for integration with non-insulin therapies. Additionally, the recent real-world analysis showed that DexCom's CGM may have a positive impact on reducing cardiovascular events in T2NIT patients, further expanding its potential market opportunity. However, risks do exist, including potential delays in new product releases and competition reducing DexCom's competitive advantage. Overall, the potential for growth and profitability make DexCom a strong choice for investors.
Bears say
DexCom is expected to face pricing headwinds in the near future, but its core growth story, attractive TAM and market dynamics, and top-tier management team make it an industry leader. Despite potential pricing challenges, the company has strong upside potential through non-intensive Type 2 adoption and the launch of new products and coverage expansions, as seen in their impressive margins and strong FCF performance. While the company's first quarter may have faced some controversy, their revenue and margins forecasts remain strong, leading to a reiteration of a Buy rating and a lowered price target of $75, reflecting a 4.7x multiple of their estimated 2027 sales.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares